Table 1A.
Studies on antithrombotic therapy in patients with stable PAD.
| Study name | Patients, number of patients with PAD | Comparison | Primary endpoint | Safety endpoint |
|---|---|---|---|---|
| Clopidogrel vs. Aspirin in Patients at Risk of Ischaemic Events (CAPRIE) (11) | Chronic CVD N = 6,452 (subgroup PAD) |
ASA 325 mg o.d. vs. Clopidogrel 75 mg o.d. | Reduction of MACE Clopidogrel vs. ASA RR 23.8% (P = 0.01) |
Clopidogrel vs. ASA IHC 0.33 vs. 0.47% (P = ns) GIB 0.52 vs. 0.72% (P = ns) |
| Examing Use of Ticagrelor in Peripheral Artery Disease (EUCLID) (12) | Symptomatic PAD N = 13,887 |
Ticagrelor 90 mg b.d. vs. Clopidogrel 75 mg o.d. | Reduction of MACE Ticagrelor vs. Clopidogrel HR [95%CI] = 1.02 [0.92–1.13] (P = ns) |
Major bleeding Ticagrelor vs. Clopidogrel HR [95%CI] = 1.10 [0.84–1.43] (P = ns) |
| Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA) (13) | Chronic CVD N = 2,838 (subgroup PAD) |
Clopidogrel 75 mg o.d. vs. Placebo in addition to ASA 75-162 mg o.d. | Reduction of MACE Clopidogrel + ASA vs. ASA HR [95%CI] = 0.85 [0.66–1.08] (P = ns) |
Severe bleeding Clopidogrel + ASA vs. ASA HR [95%CI] = 1.18 [0.86–1.60] (P = ns) |
| Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2P–TIMI 50 trial) (14) | Chronic CVD N = 3,787 (subgroup PAD) |
Vorapaxar 2.5 mg o.d. vs. Placebo in addition to single or dual antiplatelet therapy | Reduction of MACE Vorapaxar vs. placebo HR [95% CI] = 0.94 [0.78–1.14] (P = ns) |
Major bleeding Vorapaxar vs. placebo HR [95% CI] = 1.62 [1.21–2.18] (P = 0.001) |
| Prevention of Cardiovascular Events in Patients with Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin (PEGASUS) (15) | 1 to 3 years after MI N = 1,143 (subgroup PAD) |
Ticagrelor 60 mg o.d. or Ticagrelor 90 mg o.d. or placebo in addition to ASA 100 mg o.d. | Reduction of MACE Ticagrelor vs. placebo HR [95% CI] = 1.60 [1.20–2.13] (P = 0.0013) |
Major bleeding Ticagrelor vs. placebo HR [95% CI] = 1.57 [0.47–5.22] (P = ns) |
| Warfarin Antiplatelet Vascular Evaluation Trial (WAVE) (16) | PAD or carotid stenosis N = 1.767 (subgroup PAD, carotid stenosis excluded) |
VKA or placebo in addition to single antiplatelet therapy | Reduction of MACE VKA vs. placebo RR [95% CI] = 0.92 [0.73–1.16] (P = ns) |
Life-threatening bleeding VKA vs. placebo RR [95% CI] = 3.41 [1.84–6.34] (P = <0.001) |
| Cardiovascular OutcoMes for People Using Anticoagulation StrategyS (COMPASS) (8, 17) | Chronic CVD N = 5,551 (subgroup PAD, carotid stenosis excluded) |
ASA 100 mg o.d. or Rivaroxaban 5 g b.d. or ASA 100 mg and Rivaroxaban 2.5 mg b.d. | Reduction of MACE ASA vs. ASA + Rivaroxaban HR [95% CI] = 0.70 [0.56–0.88] (P = 0.002) |
Major bleeding ASA vs. ASA + Rivaroxaban HR [95% CI] = 2.12 [1.21–3.71] (P = 0.007) |
Significant P-values are displayed in bold.